Rio Tinto subsidiary Technological Resources has successfully challenged a decision by IP Australia to reject a patent application for a method of separating mined material, with a judge finding the claimed invention was not a collection of mere working directions as a delegate had found.
Two patent attorneys being sued by boutique IP firm Pizzeys Patent and Trade Mark Attorneys are resisting an application for preliminary discovery, denying the firm’s claim that they misused confidential information to poach clients.
Global solar panel manufacturer Hanwha Q CELLS wants to amend the patent behind its solar technology, more than six months after launching infringement proceedings against three rivals.
Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
Two patent attorneys who are being sued by a boutique IP firm for jumping ship to start their own business have cleared the first hurdle in their fight against preliminary discovery, after a judge found the documents relied upon by their former employer’s lawyers at Seyfarth Shaw were relevant to the case.
Novartis has applied to amend its proposed patent for an oral form of multiple sclerosis drug Gilenya, as it appeals an invalidity ruling by IP Australia for lack of inventive step.
The potential source of alleged “industrial espionage” in Motorola’s case against Hytera over the intellectual property for its digital radio mobile devices has been revealed as a mystery woman with two laptops that contained a “very large number of Motorola documents”, a court has heard.
Motorola has slammed Hytera for engaging in “industrial espionage on a grand scale”, after more than a thousand Motorola-branded documents were found in the possession of the Chinese radio maker.
An urgent injunction sought by US-based Millennium Pharmaceuticals to block generic drug maker Dr Reddy’s Laboratories from launching a cheap version of the breakthrough cancer drug Velcade has been panned as unnecessary.